Termination of Registration of a Class of Security Under Section 12(g) (15-12g)
July 06 2015 - 12:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION
AND NOTICE OF TERMINATION OF REGISTRATION UNDER
SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY
TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 000-23155
ALEXION PHARMA LLC (successor in interest to
SYNAGEVA BIOPHARMA CORP.)
(Exact name of registrant as specified in its charter)
33 Hayden Avenue
Lexington, Massachusetts 02421
(781) 357-9900
(Address,
including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, par
value $0.001
(Title of each class of securities covered by this Form)
N/A
(Titles of all other
classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to
designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
|
|
|
|
| Rule 12g-4(a)(1) |
|
x |
|
|
| Rule 12g-4(a)(2) |
|
¨ |
|
|
| Rule 12h-3(b)(1)(i) |
|
x |
|
|
| Rule 12h-3(b)(1)(ii) |
|
¨ |
|
|
| Rule 15d-6 |
|
¨ |
|
|
Approximate number of holders of record as of the certification or notice date: One
Pursuant to the requirements of the Securities Exchange Act of 1934, Alexion Pharma LLC (successor in interest to Synageva BioPharma Corp.)
has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
|
|
|
|
|
|
|
|
|
| Date: July 6, 2015 |
|
|
|
ALEXION PHARMA LLC (successor in interest to
SYNAGEVA BIOPHARMA CORP.) |
|
|
|
|
|
|
|
|
By: |
|
/s/ Michael V. Greco |
|
|
|
|
|
|
Name: |
|
Michael V. Greco
Manager |
(MM) (NASDAQ:GEVA)
Historical Stock Chart
From Apr 2024 to May 2024
(MM) (NASDAQ:GEVA)
Historical Stock Chart
From May 2023 to May 2024
